Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Real-World study tests nemolizumab for persistent eczema itch

NCT ID NCT06988605

Disease control Sponsor: Galderma R&D Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 1,000 adolescents and adults with moderate-to-severe atopic dermatitis (eczema) who are starting treatment with nemolizumab (Nemluvio®) in real-world clinics. The main goal is to see how well the drug controls skin symptoms and itching after 6 months, using doctor ratings and patient reports. Researchers will also monitor safety and long-term effects for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nemolizumab (Nemluvio®)
What this could lead to
If successful, this study could confirm that nemolizumab effectively controls itching and skin symptoms in everyday clinical practice for people with atopic dermatitis.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also early in real-world use, so long-term benefits and risks are still being assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The clinical decision for treatment with nemolizumab has to be made by the physicians independently of the participation in this NIS and prior to the informed consent process. Participants greater than or equal to (\>=) 12 years of age will be eligible for the trial.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®). * Adolescent and adult participants aged \>=12 years with moderate-to-severe AD. * Participants who signed the written informed consent form (ICF) or had it signed by their legal representative. Exclusion Criteria: * Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label. * Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline. * Participants who received nemolizumab previously. * Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    107 sites in 3 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Galderma Investigationa Site 7104

    RECRUITING

    Milford, Massachusetts, 01757, United States

  • Galderma Investigational Site # 7052

    RECRUITING

    East Syracuse, New York, 13057, United States

  • Galderma Investigational Site - 7051

    RECRUITING

    New York, New York, 10023, United States

  • Galderma Investigational Site - 7067

    NOT_YET_RECRUITING

    Tucson, Arizona, 85718, United States

  • Galderma Investigational Site - 7074

    NOT_YET_RECRUITING

    Corona, California, 92882, United States

  • Galderma Investigational Site - 8282

    NOT_YET_RECRUITING

    Mount Kisco, New York, 10549-3035, United States

  • Galderma Investigational Site - 8535

    RECRUITING

    Phoenix, Arizona, 85032-2238, United States

  • Galderma Investigational Site - 8893

    ACTIVE_NOT_RECRUITING

    Birmingham, Alabama, 35244, United States

  • Galderma Investigational Site - Site 7080

    RECRUITING

    Auburn, New York, 13021, United States

  • Galderma Investigational Site 5131

    RECRUITING

    Harrogate, North Yorkshire, HG2 7SX, United Kingdom

  • Galderma Investigational Site 5210

    RECRUITING

    London, E11 1NR, United Kingdom

  • Galderma Investigational Site 5408

    RECRUITING

    London, Hampshire, NW3 2QG, United Kingdom

  • Galderma Investigational Site 5431

    RECRUITING

    Redhill, RH1 5RH, United Kingdom

  • Galderma Investigational Site 5944

    RECRUITING

    Wolverhampton, WV10 0QP, United Kingdom

  • Galderma Investigational Site 5989

    RECRUITING

    Swansea, SA2 8QA, United Kingdom

  • Galderma Investigational Site 6013

    RECRUITING

    Lübeck, 23562, Germany

  • Galderma Investigational Site 6066

    RECRUITING

    Buxtehude, 21614, Germany

  • Galderma Investigational Site 6366

    RECRUITING

    Berlin, 13086, Germany

  • Galderma Investigational Site 6368

    RECRUITING

    London, SE1 9RT, United Kingdom

  • Galderma Investigational Site 6369

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

  • Galderma Investigational Site 6370

    RECRUITING

    Haslach im Kinzigtal, 77716, Germany

  • Galderma Investigational Site 6371

    RECRUITING

    Oberursel, 61440, Germany

  • Galderma Investigational Site 6372

    RECRUITING

    Quedlinburg, 6484, Germany

  • Galderma Investigational Site 6373

    RECRUITING

    Mainz, 55128, Germany

  • Galderma Investigational Site 6374

    RECRUITING

    Karlsruhe, Baden-Wurttemberg, 76133, Germany

  • Galderma Investigational Site 6375

    RECRUITING

    Bridgend, CF31 1RQ, United Kingdom

  • Galderma Investigational Site 6383

    RECRUITING

    Augsburg, 86150, Germany

  • Galderma Investigational Site 6384

    RECRUITING

    Koblenz, 56068, Germany

  • Galderma Investigational Site 6385

    RECRUITING

    Berlin, 10117, Germany

  • Galderma Investigational Site 6386

    RECRUITING

    Bielefeld, 33647, Germany

  • Galderma Investigational Site 6387

    RECRUITING

    Ahaus, 48683, Germany

  • Galderma Investigational Site 6388

    RECRUITING

    Epsom, KT18 7EG, United Kingdom

  • Galderma Investigational Site 6389

    RECRUITING

    Sheffield, South Yorkshire, S10 2TH, United Kingdom

  • Galderma Investigational Site 6390

    RECRUITING

    Pforzheim, 75172, Germany

  • Galderma Investigational Site 6392

    RECRUITING

    Birmingham, West Midlands, B15 2GW, United Kingdom

  • Galderma Investigational Site 6393

    RECRUITING

    Kingston upon Thames, KT2 7QB, United Kingdom

  • Galderma Investigational Site 6394

    RECRUITING

    Harrow, HA3 7LT, United Kingdom

  • Galderma Investigational Site 6395

    RECRUITING

    London, Surrey, SE5 9RS, United Kingdom

  • Galderma Investigational Site 6396

    RECRUITING

    Manchester, M23 2SY, United Kingdom

  • Galderma Investigational Site 6397

    RECRUITING

    York, Yorkshire, YO31 8HE, United Kingdom

  • Galderma Investigational Site 6398

    RECRUITING

    Bernau bei Berlin, 16321, Germany

  • Galderma Investigational Site 6399

    RECRUITING

    Watford, Hertfordshire, WD18 0HB, United Kingdom

  • Galderma Investigational Site 6400

    RECRUITING

    Kings Lynn, Norfolk, PE30 4ET, United Kingdom

  • Galderma Investigational Site 6401

    RECRUITING

    Southampton, Hampshire, SO16 6YD, United Kingdom

  • Galderma Investigational Site 6402

    RECRUITING

    Metropolitan Borough of Wirral, CH49 5PE, United Kingdom

  • Galderma Investigational Site 6403

    RECRUITING

    Sandbach, CW11, United Kingdom

  • Galderma Investigational Site 6404

    RECRUITING

    Leeds, West Yorkshire, LS9 7TF, United Kingdom

  • Galderma Investigational Site 6411

    RECRUITING

    Oranienburg, 16515, Germany

  • Galderma Investigational Site 6412

    RECRUITING

    Langenau, Baden-Wurttemberg, 89129, Germany

  • Galderma Investigational Site 6414

    RECRUITING

    Gladbeck, 45964, Germany

  • Galderma Investigational Site 6415

    RECRUITING

    Liverpool, L14 5AB, United Kingdom

  • Galderma Investigational Site 6416

    RECRUITING

    Augsburg, Bavaria, 86179, Germany

  • Galderma Investigational Site 6417

    RECRUITING

    Regensburg, Bavaria, 93053, Germany

  • Galderma Investigational Site 6418

    RECRUITING

    Großenhain, 1558, Germany

  • Galderma Investigational Site 6419

    RECRUITING

    Remscheid, North Rhine-Westphalia, 42897, Germany

  • Galderma Investigational Site 6420

    RECRUITING

    Hersbruck, 91217, Germany

  • Galderma Investigational Site 6666

    NOT_YET_RECRUITING

    Kirkcaldy, KY2 5AH, United Kingdom

  • Galderma Investigational Site 7054

    RECRUITING

    Tampa, Florida, 33609-2230, United States

  • Galderma Investigational Site 7055

    RECRUITING

    Portsmouth, New Hampshire, 03801-7156, United States

  • Galderma Investigational Site 7057

    RECRUITING

    Lee's Summit, Missouri, 64064, United States

  • Galderma Investigational Site 7058

    RECRUITING

    Chicago, Illinois, 60641, United States

  • Galderma Investigational Site 7059

    RECRUITING

    Fairfield, Connecticut, 76824, United States

  • Galderma Investigational Site 7060

    RECRUITING

    Phoenix, Arizona, 85008-3884, United States

  • Galderma Investigational Site 7061

    NOT_YET_RECRUITING

    Castle Rock, Colorado, 80109-8034, United States

  • Galderma Investigational Site 7062

    NOT_YET_RECRUITING

    Edinburg, Texas, 78539-4660, United States

  • Galderma Investigational Site 7063

    RECRUITING

    Cutler Bay, Florida, 33157, United States

  • Galderma Investigational Site 7064

    NOT_YET_RECRUITING

    Santa Monica, California, 90404-2216, United States

  • Galderma Investigational Site 7065

    RECRUITING

    Brighton, Massachusetts, 02135, United States

  • Galderma Investigational Site 7066

    NOT_YET_RECRUITING

    Auburn Hills, Michigan, 48326-3396, United States

  • Galderma Investigational Site 7068

    RECRUITING

    Rockville, Maryland, 20850-6243, United States

  • Galderma Investigational Site 7069

    RECRUITING

    Sugar Land, Texas, 77478-3842, United States

  • Galderma Investigational Site 7070

    NOT_YET_RECRUITING

    North Miami Beach, Florida, 33162-4708, United States

  • Galderma Investigational Site 7071

    RECRUITING

    Caledonia, Michigan, 49316-7478, United States

  • Galderma Investigational Site 7072

    NOT_YET_RECRUITING

    Troy, Michigan, 48084-5260, United States

  • Galderma Investigational Site 7073

    RECRUITING

    Gresham, Oregon, 97030-2923, United States

  • Galderma Investigational Site 7078

    RECRUITING

    Miami, Florida, 33173, United States

  • Galderma Investigational Site 7079

    NOT_YET_RECRUITING

    Vienna, Virginia, 22182, United States

  • Galderma Investigational Site 7081

    RECRUITING

    Dayton, Ohio, 45414-2799, United States

  • Galderma Investigational Site 7082

    RECRUITING

    Cedar Park, Texas, 78613-7875, United States

  • Galderma Investigational Site 7083

    NOT_YET_RECRUITING

    West Lafayette, Indiana, 47906-1569, United States

  • Galderma Investigational Site 7085

    NOT_YET_RECRUITING

    Bountiful, Utah, 84010-4801, United States

  • Galderma Investigational Site 7087

    NOT_YET_RECRUITING

    Coral Gables, Florida, 33134-2073, United States

  • Galderma Investigational Site 7088

    RECRUITING

    Grapevine, Texas, 76051, United States

  • Galderma Investigational Site 7090

    RECRUITING

    St. Petersburg, Florida, 33713-8012, United States

  • Galderma Investigational Site 7098

    RECRUITING

    Columbia, Maryland, 21045-2336, United States

  • Galderma Investigational Site 7099

    NOT_YET_RECRUITING

    Los Angeles, California, 90024-2801, United States

  • Galderma Investigational Site 7101

    NOT_YET_RECRUITING

    Jupiter, Florida, 33477, United States

  • Galderma Investigational Site 7103

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Galderma Investigational Site 7106

    NOT_YET_RECRUITING

    Bluffton, South Carolina, 29910, United States

  • Galderma Investigational Site 7107

    NOT_YET_RECRUITING

    Thousand Oaks, California, 91360-7746, United States

  • Galderma Investigational Site 7108

    NOT_YET_RECRUITING

    Grandville, Michigan, 49418, United States

  • Galderma Investigational Site 7109

    RECRUITING

    New York, New York, 10028, United States

  • Galderma Investigational Site 7112

    NOT_YET_RECRUITING

    Oakland Park, Florida, 33334, United States

  • Galderma Investigational Site 7134

    RECRUITING

    Hollywood, Florida, 33021-6748, United States

  • Galderma Investigational Site 8012

    RECRUITING

    Glenn Dale, Maryland, 20769-9182, United States

  • Galderma Investigational Site 8142

    RECRUITING

    Indianapolis, Indiana, 46250-2041, United States

  • Galderma Investigational Site 8224

    RECRUITING

    Fremont, California, 94538-1603, United States

  • Galderma Investigational Site 8238

    RECRUITING

    Dallas, Texas, 75230-5808, United States

  • Galderma Investigational Site 8279

    NOT_YET_RECRUITING

    New York, New York, 10075-0337, United States

  • Galderma Investigational Site 8553

    RECRUITING

    Newport Beach, California, 92663-3606, United States

  • Galderma Investigational Site 8559

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19103-4738, United States

  • Galderma Investigational Site 8597

    NOT_YET_RECRUITING

    Boca Raton, Florida, 33431-5133, United States

  • Galderma Investigational Site 8618

    NOT_YET_RECRUITING

    Waco, Texas, 76710-4023, United States

  • Galderma Investigational Site 8636

    NOT_YET_RECRUITING

    Fountain Valley, California, 92708-3701, United States

  • Galderma Investigational Site 8725

    RECRUITING

    Morgantown, West Virginia, 26505-1873, United States

  • Galderma Investigational Site 8848

    RECRUITING

    Las Vegas, Nevada, 89144-0518, United States

  • Galderma Investigative Site 6172

    RECRUITING

    Berlin, 12203, Germany

  • Galdrma Investigational Site - 7077

    RECRUITING

    Phoenix, Arizona, 85006-2754, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.